In an effort to expand access to affordable, quality maternal health (MH) medicines, Jhpiego has built business cases for investing in high-quality MH drugs in low-resource settings. These business cases collectively map manufacturers of MH medicines, approximate market sizes for the medicines, and characterize market dynamics. Ultimately, we hope to promote investment in the production and supply of high-quality MH products that will be affordable for African and southeast Asian markets. Support for this project was provided by PATH on behalf of the Reproductive Health Supplies Coalition. This effort has generated three written case studies: on oxytocin, misoprostol, and magnesium sulfate (MgSO4). In addition, an “Accelovate Maternal Health Drug Business Assessments” Excel file contains global market data pertaining to these three products. The Excel file will allow users to examine our data and to manipulate assumptions to generate tailored market projections.
This User Guide supports the Excel file containing global market data related to MH products for the prevention and treatment of postpartum hemorrhage (PPH) and preeclampsia/eclampsia (PE/E).